We report on the structural transformations of Bioglass® during thermal treatments. Just after the glassy transition, at 550 °C, a glassy phase separation occurs at 580 °C, with the appearance of one silicateand one phosphate-rich phase. It is followed by the crystallization of the major phase Na2CaSi2O6, from 610 to 700 °C and of the secondary phase, silicorhenanite, at 800 °C. The latter evol...

Polymer scaffold systems consisting of poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) have proven to be possible matrices for the three-dimensional growth of chondrocyte cultures. However, the engineered cartilage grown on these PHBV scaffolds is currently unsatisfactory for clinical applications due to PHBV's poor hydrophilicity, resulting in inadequate thickness and poor biomechanical proper...

This study aimed to investigate bone responses to a novel bioactive fully crystallized glass-ceramic of the quaternary system P(2)O(5)-Na(2)O-CaO-SiO(2) (Biosilicate®). Although a previous study demonstrated positive effects of Biosilicate® on in vitro bone-like matrix formation, its in vivo effect was not studied yet. Male Wistar rats (n = 40) with tibial defects were used. Four experimental g...

Fundamental aspects of biomineralization may be important in order to understand and improve calcification onto the surface of biomaterials. The biomineralization process is mainly followed in vitro by assessing the evolution of the apatite layer that is formed upon immersion of the material in Simulated Body Fluid (SBF). In this work we propose an innovative methodology to monitor apatite depo...

Dental implant failure remains a prevalent problem around the globe. The integration of implants at interface soft and hard tissues is complex susceptible to instability infections. Modifications surface titanium have been developed improve performance, yet insufficient biofilm formation remain major problems. Introducing nanostructures on augment implant–tissue contact holds promise for facili...

PURPOSE This study proposes an alternative preparation method of platelet-rich plasma (PRP). Specifically, we compare the use of thrombin receptor agonist peptide-6 (TRAP) and bovine thrombin as a clotting agent in the preparation of PRP. MATERIALS AND METHODS PRP was prepared by centrifugation and clotted with thrombin or TRAP. In vitro clotting times were monitored as a function of TRAP con...